Evaluate the Safety and Efficacy of Almonertinib in the Treatment of Advanced NSCLC Patients With EGFR-sensitive Mutations Who Are Safety Intolerant After Osimertinib Treatment: a Prospective, Multi-center, Single-arm Clinical Trial
Latest Information Update: 19 Jan 2024
At a glance
- Drugs Aumolertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms ACTIVE
- 09 Aug 2022 Study design presented at the 2022 World Conference on Lung Cancer
- 13 May 2021 New trial record